These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27240054)

  • 1. Recent innovations in mRNA vaccines.
    Ulmer JB; Geall AJ
    Curr Opin Immunol; 2016 Aug; 41():18-22. PubMed ID: 27240054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.
    Deering RP; Kommareddy S; Ulmer JB; Brito LA; Geall AJ
    Expert Opin Drug Deliv; 2014 Jun; 11(6):885-99. PubMed ID: 24665982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-based vaccines.
    Ulmer JB; Mason PW; Geall A; Mandl CW
    Vaccine; 2012 Jun; 30(30):4414-8. PubMed ID: 22546329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of anthrax DNA vaccines.
    Ferrari ME; Hermanson G; Rolland A
    Curr Opin Mol Ther; 2004 Oct; 6(5):506-12. PubMed ID: 15537052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA: the new revolution in nucleic acid vaccines.
    Geall AJ; Mandl CW; Ulmer JB
    Semin Immunol; 2013 Apr; 25(2):152-9. PubMed ID: 23735226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination.
    Tombácz I; Weissman D; Pardi N
    Methods Mol Biol; 2021; 2197():13-31. PubMed ID: 32827130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-amplifying mRNA vaccines.
    Brito LA; Kommareddy S; Maione D; Uematsu Y; Giovani C; Berlanda Scorza F; Otten GR; Yu D; Mandl CW; Mason PW; Dormitzer PR; Ulmer JB; Geall AJ
    Adv Genet; 2015; 89():179-233. PubMed ID: 25620012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A blueprint for DNA vaccine design.
    Iurescia S; Fioretti D; Rinaldi M
    Methods Mol Biol; 2014; 1143():3-10. PubMed ID: 24715278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmid DNA- and messenger RNA-based anti-cancer vaccination.
    Weide B; Garbe C; Rammensee HG; Pascolo S
    Immunol Lett; 2008 Jan; 115(1):33-42. PubMed ID: 18006079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-replicating alphavirus RNA vaccines.
    Ljungberg K; Liljeström P
    Expert Rev Vaccines; 2015 Feb; 14(2):177-94. PubMed ID: 25269775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates.
    Simon AJ; Casimiro DR; Finnefrock AC; Davies ME; Tang A; Chen M; Chastain M; Kath GS; Chen L; Shiver JW
    Vaccine; 2008 Sep; 26(40):5202-9. PubMed ID: 18472195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of the immunogenicity of an alphavirus replicon-based DNA vaccine against classical swine fever by electroporation and coinjection with a plasmid expressing porcine interleukin 2.
    Tian DY; Sun Y; Wai SF; Lee FK; Meng QL; Suen KM; Wang N; Han W; Li S; Li YF; Li D; Ling LJ; Liao YJ; Qiu HJ
    Vaccine; 2012 May; 30(24):3587-94. PubMed ID: 22469861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coadministration of a Plasmid Encoding HIV-1 Gag Enhances the Efficacy of Cancer DNA Vaccines.
    Lambricht L; Vanvarenberg K; De Beuckelaer A; Van Hoecke L; Grooten J; Ucakar B; Lipnik P; Sanders NN; Lienenklaus S; Préat V; Vandermeulen G
    Mol Ther; 2016 Sep; 24(9):1686-96. PubMed ID: 27434590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live attenuated bacteria as vectors to deliver plasmid DNA vaccines.
    Dietrich G; Spreng S; Favre D; Viret JF; Guzman CA
    Curr Opin Mol Ther; 2003 Feb; 5(1):10-9. PubMed ID: 12669465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Messenger RNA-based vaccines: progress, challenges, applications.
    Kramps T; Probst J
    Wiley Interdiscip Rev RNA; 2013; 4(6):737-49. PubMed ID: 23893949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-launched live-attenuated vaccines for biodefense applications.
    Pushko P; Lukashevich IS; Weaver SC; Tretyakova I
    Expert Rev Vaccines; 2016 Sep; 15(9):1223-34. PubMed ID: 27055100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms for enhanced DNA vaccine immunogenicity.
    Li L; Petrovsky N
    Expert Rev Vaccines; 2016; 15(3):313-29. PubMed ID: 26707950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Present status of basic studies and development of DNA vaccines].
    Kurane I
    Nihon Rinsho; 1999 Apr; 57(4):975-81. PubMed ID: 10222799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical adjuvants for plasmid DNA vaccines.
    Greenland JR; Letvin NL
    Vaccine; 2007 May; 25(19):3731-41. PubMed ID: 17350735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of human DNA vaccines.
    Li L; Saade F; Petrovsky N
    J Biotechnol; 2012 Dec; 162(2-3):171-82. PubMed ID: 22981627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.